U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07445815) titled 'A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody' on Jan. 26.
Brief Summary: A Phase II, Single-Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Subjects
Study Start Date: Jan. 31
Study Type: INTERVENTIONAL
Condition:
Rabies (Healthy Volunteers)
Intervention:
DRUG: Recombinant Human Rabies Virus Monoclonal Antibody Injection
On Day 0, administer via intramuscular injection into the lateral thigh. It is strictly prohibited to use the same syringe as the ...